Outcomes with single agent LIPO-DOX in platinum-resistant ovarian and fallopian tube cancers and primary peritoneal adenocarcinoma - Chiang Mai University Hospital experience
Background: Single pegylated liposomal doxorubicin (PLD) is commonly used as a salvage treatment in platinum-resistant ovarian cancer, fallopian tube cancer and primary peritoneal adenocarcinoma (PPA) with a satisfactory outcome. However, the data for second generation PLD administered in this setti...
Saved in:
Main Authors: | Suprasert P., Manopunya M., Cheewakriangkrai C. |
---|---|
Format: | Article |
Language: | English |
Published: |
Asian Pacific Organization for Cancer Prevention
2014
|
Online Access: | http://www.scopus.com/inward/record.url?eid=2-s2.0-84896820972&partnerID=40&md5=09179a068b0dbcb9af6131afa102ac4c http://www.ncbi.nlm.nih.gov/pubmed/24606432 http://cmuir.cmu.ac.th/handle/6653943832/1702 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Chiang Mai University |
Language: | English |
Similar Items
-
Outcomes with single agent LIPO-DOX in platinum-resistant ovarian and fallopian tube cancers and primary peritoneal adenocarcinoma - Chiang Mai University Hospital experience
by: Prapaporn Suprasert, et al.
Published: (2018) -
Outcomes with single agent LIPO-DOX in platinum-resistant ovarian and fallopian tube cancers and primary peritoneal adenocarcinoma - Chiang Mai University Hospital experience
by: Prapaporn Suprasert, et al.
Published: (2018) -
Outcome of single agent generic gemcitabine in platinum-resistant ovarian cancer, fallopian tube cancer and primary peritoneal adenocarcinoma.
by: Suprasert P., et al.
Published: (2014) -
Outcome of single agent generic gemcitabine in platinum-resistant ovarian cancer, fallopian tube cancer and primary peritoneal adenocarcinoma
by: Suprasert P., et al.
Published: (2014) -
Outcome of single agent generic gemcitabine in platinum- resistant ovarian cancer, fallopian tube cancer and primary peritoneal adenocarcinoma
by: Suprasert P., et al.
Published: (2014)